BA/BE Studies for Early Termination [Two-Stage / GS Designs]

posted by balakotu – India, 2015-09-22 15:05 (3110 d 06:04 ago) – Posting: # 15441
Views: 5,592

Dear all,

We are planning to conduct one "Replicate 4-period" bio-equivalence study with 70 subjects.

After completion of clinical phase we will analyze only 40 subjects.

If 40 subject’s data is shown bio-equivalent then we will stop the analysis of remaining 30 subjects. If the data is predictable then we will analyze remaining 30 subjects.

Please clarify whether this approach/design is acceptable to regulatory are not.

Regards

Kotu


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
98 visitors (0 registered, 98 guests [including 7 identified bots]).
Forum time: 20:09 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5